learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 26 resultslearn GT20029
research compound made to degrade androgen receptors in scalp
learn Hair Multiplication
extract, clone, and reinsert your own hair cells
learn Overview
learn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
Research
5 / 1000+ results
research Estradiol Protects Hair Cells From Cisplatin-Induced Ototoxicity Via Nrf2 Activation
Estradiol may protect ear cells from hearing loss caused by a chemotherapy drug by activating a protective pathway.
research Aqueous Extract of Mentha Suaveolens Induces Nrf-2 Activation and Expression of Antioxidant and Detoxifying Enzymes in Human Keratinocyte HaCaT
Mint water extract boosts protective enzymes in skin cells.
research Claudin-1 and Claudin-3 Maintain Proper Hair Follicle Structure and Regulate Telogen Effluvium
Claudin-1 and Claudin-3 are crucial for keeping hair follicle structure and preventing a type of hair loss called telogen effluvium.
research Red Ginseng (Panax Ginseng Meyer) Oil: A Comprehensive Review of Extraction Technologies, Chemical Composition, Health Benefits, Molecular Mechanisms, and Safety
Red ginseng oil is believed to have various health benefits and is safe, but more research is needed to fully understand how it works.
research Endocannabinoid-Like Molecule Oleoylethanolamide Promotes Sebaceous Lipid Synthesis
Oleoylethanolamide (OEA) safely boosts fat production in skin cells and may help treat dry skin and reduce inflammation.
Community Join
5 / 1000+ resultscommunity Phase II Clinical Trial for TDM-105795 started recruiting
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community GT20029 phase II results release date?
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.